Dynavax Technologies Gross Profit 2010-2022 | DVAX

Dynavax Technologies gross profit from 2010 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Dynavax Technologies Annual Gross Profit
(Millions of US $)
2021 $266
2020 $35
2019 $25
2018 $-3
2017 $0
2016 $11
2015 $4
2014 $11
2013 $11
2012 $10
2011 $22
2010 $24
2009 $40
Dynavax Technologies Quarterly Gross Profit
(Millions of US $)
2022-03-31 $74
2021-12-31 $121
2021-09-30 $48
2021-06-30 $38
2021-03-31 $59
2020-12-31 $15
2020-09-30 $9
2020-06-30 $2
2020-03-31 $9
2019-12-31 $8
2019-09-30 $7
2019-06-30 $6
2019-03-31 $4
2018-12-31 $4
2018-09-30 $-2
2018-06-30 $-4
2018-03-31 $-0
2017-12-31 $0
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $7
2016-09-30 $0
2016-06-30 $3
2016-03-31 $1
2015-12-31 $1
2015-09-30 $1
2015-06-30 $2
2015-03-31 $1
2014-12-31 $2
2014-09-30 $2
2014-06-30 $3
2014-03-31 $3
2013-12-31 $3
2013-09-30 $3
2013-06-30 $3
2013-03-31 $2
2012-12-31 $2
2012-09-30 $3
2012-06-30 $3
2012-03-31 $2
2011-12-31 $11
2011-09-30 $1
2011-06-30 $7
2011-03-31 $2
2010-12-31 $2
2010-09-30 $12
2010-06-30 $2
2010-03-31 $8
2009-12-31 $2
2009-09-30 $3
2009-06-30 $16
2009-03-31 $19
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.441B $0.439B
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.299B 9.94
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.420B 16.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.085B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.716B 0.00
Emergent Biosolutions (EBS) United States $1.842B 7.89
Arcus Biosciences (RCUS) United States $1.368B 34.69
Myovant Sciences (MYOV) United Kingdom $0.984B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.517B 0.00
Gelesis Holdings (GLS) United States $0.358B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.117B 24.10
SQZ Biotechnologies (SQZ) United States $0.095B 0.00